Healthcare provider profile · identity verified

Willard K Schanhofer, MD

Family Practice · TOMAH, WI · NPI 1730179862

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	315	86
Omeprazole	Omeprazole	274	70
Losartan Potassium	Losartan Potassium	188	54
Metoprolol Succinate	Metoprolol Succinate	176	58
Amlodipine Besylate	Amlodipine Besylate	174	52
Eliquis	Apixaban	170	35
Gabapentin	Gabapentin	167	47
Levothyroxine Sodium	Levothyroxine Sodium	164	44
Metformin Hcl Er	Metformin Hcl	156	36
Furosemide	Furosemide	130	39
Metoprolol Tartrate	Metoprolol Tartrate	128	34
Tamsulosin Hcl	Tamsulosin Hcl	124	33
Glipizide Er	Glipizide	114	31
Albuterol Sulfate Hfa	Albuterol Sulfate	111	32
Potassium Chloride	Potassium Chloride	109	36
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	107	22
Lisinopril	Lisinopril	103	33
Rosuvastatin Calcium	Rosuvastatin Calcium	91	27
Simvastatin	Simvastatin	91	28
Pravastatin Sodium	Pravastatin Sodium	86	24
Hydrochlorothiazide	Hydrochlorothiazide	80	22
Fluoxetine Hcl	Fluoxetine Hcl	79	18
Tramadol Hcl	Tramadol Hcl	77	19
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	74	23
Trazodone Hcl	Trazodone Hcl	74	13
Famotidine	Famotidine	73	22
Sertraline Hcl	Sertraline Hcl	68	18
Alprazolam	Alprazolam	66	17
Pantoprazole Sodium	Pantoprazole Sodium	66	17
Warfarin Sodium	Warfarin Sodium	64	19
Jardiance	Empagliflozin	63	14
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	63	suppressed
Spironolactone	Spironolactone	62	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	58	16
Prednisone	Prednisone	55	31
Montelukast Sodium	Montelukast Sodium	54	12
Metformin Hcl	Metformin Hcl	51	16
Bupropion Hcl Sr	Bupropion Hcl	50	suppressed
Lovastatin	Lovastatin	41	suppressed
Finasteride	Finasteride	40	11
Fluticasone Propionate	Fluticasone Propionate	40	15
Escitalopram Oxalate	Escitalopram Oxalate	39	12
Allopurinol	Allopurinol	37	suppressed
Celecoxib	Celecoxib	37	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	36	12
Trulicity	Dulaglutide	35	suppressed
Ozempic	Semaglutide	34	suppressed
Baclofen	Baclofen	33	suppressed
Clopidogrel	Clopidogrel Bisulfate	33	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	33	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	33	21
Duloxetine Hcl	Duloxetine Hcl	32	suppressed
Ipratropium Bromide	Ipratropium Bromide	32	13
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	30	suppressed
Hydralazine Hcl	Hydralazine Hcl	29	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	28	suppressed
Citalopram Hbr	Citalopram Hydrobromide	28	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	27	suppressed
Lorazepam	Lorazepam	27	suppressed
Amoxicillin	Amoxicillin	25	suppressed
Olanzapine	Olanzapine	25	suppressed
Oxycodone Hcl	Oxycodone Hcl	25	suppressed
Solifenacin Succinate	Solifenacin Succinate	25	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	25	suppressed
Carbamazepine	Carbamazepine	24	suppressed
Carvedilol	Carvedilol	24	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	24	suppressed
Mirtazapine	Mirtazapine	24	suppressed
Topiramate	Topiramate	24	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	23	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	23	suppressed
Fenofibrate	Fenofibrate	23	suppressed
Torsemide	Torsemide	23	suppressed
Atenolol	Atenolol	22	suppressed
Januvia	Sitagliptin Phosphate	22	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	22	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	20	19
Alendronate Sodium	Alendronate Sodium	19	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	19	11
Glimepiride	Glimepiride	19	suppressed
Mometasone Furoate	Mometasone Furoate	19	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	19	suppressed
Tizanidine Hcl	Tizanidine Hcl	19	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	18	suppressed
Synthroid	Levothyroxine Sodium	18	suppressed
Meloxicam	Meloxicam	17	suppressed
Norethindrone-E.Estradiol-Iron	Norethindrone-E.Estradiol-Iron	16	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	16	suppressed
Pregabalin	Pregabalin	16	suppressed
Cefdinir	Cefdinir	15	14
Advair Hfa	Fluticasone Propion/Salmeterol	14	suppressed
Ezetimibe	Ezetimibe	14	suppressed
Glipizide	Glipizide	14	suppressed
Paroxetine Hcl	Paroxetine Hcl	14	suppressed
Ventolin Hfa	Albuterol Sulfate	14	suppressed
Breo Ellipta	Fluticasone/Vilanterol	13	suppressed
Doxepin Hcl	Doxepin Hcl	13	suppressed
Levetiracetam	Levetiracetam	13	suppressed
Methotrexate	Methotrexate Sodium	13	suppressed
Xarelto	Rivaroxaban	13	suppressed
Clonazepam	Clonazepam	12	suppressed
Ketoconazole	Ketoconazole	12	suppressed
Metolazone	Metolazone	12	suppressed
Risperidone	Risperidone	12	suppressed
Aripiprazole	Aripiprazole	11	suppressed
Diclofenac Sodium	Diclofenac Sodium	11	suppressed
Humalog Kwikpen U-100	Insulin Lispro	11	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error